New Data Confirms Early Implantation of Impella 2.5 Prior to PCI Improves Survival in Shock Patients
DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new results from a multicenter retrospective study demonstrating that early initiation of support with Impella® 2.5 prior to revascularization improves survival in emergent patients as compared to those receiving Impella 2.5 support after percutaneous coronary intervention (PCI). Specifically, the analysis demonstrated that shock patients that received Impella before revascularization had a higher survival rate (65% vs. 39%, p=0.007 respectively, N=119).
The results of the study were presented today by William ONeill, M.D. of the University of Miami, at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) meeting and included 119 patients receiving emergent PCI with Impella at 32 U.S. centers.
The data from this analysis supports the recently released new ACCF/AHA/SCAI guidelines which included Impella as a Class I recommendation for cardiogenic shock after STEMI.
5.2.3 Cardiogenic Shock Class I: Recommendation: "A hemodynamic support device is recommended for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy (384,424–427). (Level of Evidence: B)."
This is an ongoing registry that continues to analyze this data and collect data for the Impella patient population. The slides from this presentation will be made available on www.TCTMD.com on Friday, November 11, 2011.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.